• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
MSB

MESOBLAST LIMITED - Announcements

0.44% ! $2.28
Market Cap $2.918B  !

Mesoblast Limited is an Australia-based company, which is engaged in developing... Mesoblast Limited is an Australia-based company, which is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. It has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of late-stage product candidates. It is developing product candidates for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Remestemcel-L is being developed for inflammatory diseases in children and adults including steroid refractory acute graft versus host disease, and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for advanced chronic heart failure (REVASCOR) and chronic low back pain (MPC-06-ID). Two products have been commercialized in Japan and Europe by the Company's licensees. It has established commercial partnerships in Europe and China for certain Phase III assets.More

Announcements



MSB Preliminary Final Report including Appendix 4EPRICE SENSITIVE30/08/18 download Created with Sketch. 1.6MB
MSB UPDATE ON TASLY TRANSACTIONPRICE SENSITIVE29/08/18 download Created with Sketch. 89.39KB
MSB Appendix 4C - quarterlyPRICE SENSITIVE31/07/18 download Created with Sketch. 117.52KB
MSB Initial Director's Interest Notice18/07/18 download Created with Sketch. 62.49KB
MSB MSB Enters Into Cardiovascular Alliance For China With TaslyPRICE SENSITIVE17/07/18 download Created with Sketch. 80.49KB
MSB Director Appointment/Resignation11/07/18 download Created with Sketch. 89.85KB
MSB Appendix 3B10/07/18 download Created with Sketch. 184.33KB
MSB MSB Enters Into US$50M Financing With NovaQuest CapitalPRICE SENSITIVE02/07/18 download Created with Sketch. 80.37KB
MSB Initial and Final Directors' Interest Notices25/06/18 download Created with Sketch. 140.45KB
MSB ISSCR Presentation on P3 GVHD Trial Survival Benefits22/06/18 download Created with Sketch. 1.77MB
MSB Key Day 100 Survival Results In P3 GvHD TrialPRICE SENSITIVE21/06/18 download Created with Sketch. 76.22KB
MSB Director Appointment/Resignation19/06/18 download Created with Sketch. 74.62KB
MSB MSB Provides Q3 Financial Results and Operational Highlights31/05/18 download Created with Sketch. 212.11KB
MSB Mesoblast Appoints New Chief Financial Officer31/05/18 download Created with Sketch. 74.97KB
MSB Third Quarter Results Presentation31/05/18 download Created with Sketch. 965.73KB
MSB Third Quarter Financial Results on Form 6-KPRICE SENSITIVE31/05/18 download Created with Sketch. 515.82KB
MSB Partnership For Allogeneic Cell-based Cancer ImmunotherapiesPRICE SENSITIVE29/05/18 download Created with Sketch. 77.36KB
MSB Cleansing notice and Appendix 3B15/05/18 download Created with Sketch. 233.86KB
MSB MSB P3 Results For GVHD Presented At ISCT Meeting08/05/18 download Created with Sketch. 95.17KB
MSB MSB Cell Therapies Featured At Vatican Healthcare Conference01/05/18 download Created with Sketch. 73KB
MSB Appendix 4C - quarterlyPRICE SENSITIVE30/04/18 download Created with Sketch. 114.44KB
MSB MSB Clinical Program Update For MPC-150-IM In Heart Failure18/04/18 download Created with Sketch. 106.86KB
MSB Mesoblast Phase 3 CLBP Trial Completes Enrollment29/03/18 download Created with Sketch. 99.5KB
MSB Change in substantial holding09/03/18 download Created with Sketch. 187.57KB
MSB MSB Enters Into $75 Million Non-Dilutive Credit FacilityPRICE SENSITIVE07/03/18 download Created with Sketch. 91.99KB
MSB Mesoblast Provides Half Year Results and Corporate Update28/02/18 download Created with Sketch. 237.2KB
MSB Half Year Results Presentation28/02/18 download Created with Sketch. 3.21MB
MSB Half Year Report and Accounts (including Appendix 4D)PRICE SENSITIVE28/02/18 download Created with Sketch. 558.51KB
MSB GVHD Day 28 Results PresentationPRICE SENSITIVE23/02/18 download Created with Sketch. 1.85MB
MSB Primary Endpoint Successfully Achieved in MSB P3 GVHD TrialPRICE SENSITIVE22/02/18 download Created with Sketch. 103.81KB
MSB Appendix 4C - quarterlyPRICE SENSITIVE31/01/18 download Created with Sketch. 96.37KB
MSB Appendix 3B with prospectusPRICE SENSITIVE19/01/18 download Created with Sketch. 481.29KB
MSB Presentation to J.P. Morgan 2018 Healthcare Conference12/01/18 download Created with Sketch. 3.6MB
MSB Presentation at JP Morgan Healthcare Conference11/01/18 download Created with Sketch. 69.98KB
MSB Change of Director's Interest Notice22/12/17 download Created with Sketch. 88.88KB
MSB Mesoblast Receives RMAT For LVAD Heart Failure PatientsPRICE SENSITIVE21/12/17 download Created with Sketch. 86.83KB
MSB Release of shares from voluntary escrow20/12/17 download Created with Sketch. 83.61KB
MSB Mesoblast's P3 GVHD Trial Completes EnrollmentPRICE SENSITIVE20/12/17 download Created with Sketch. 93.71KB
MSB Mesoblast Grants TiGenix License For Treatment of FistulaePRICE SENSITIVE15/12/17 download Created with Sketch. 73.63KB
MSB MSB Named Global Technology Leader In Cell Therapy IndustryPRICE SENSITIVE08/12/17 download Created with Sketch. 90.71KB
MSB Change in substantial holding07/12/17 download Created with Sketch. 280.18KB
MSB Change in substantial holding05/12/17 download Created with Sketch. 291.65KB
MSB Response to ASX Aware Letter QueryPRICE SENSITIVE17/11/17 download Created with Sketch. 508.34KB
MSB Results of Meeting16/11/17 download Created with Sketch. 172.37KB
MSB CEO Presentation to 2017 Annual General Meeting16/11/17 download Created with Sketch. 3.72MB
MSB Chairman's Address to Shareholders16/11/17 download Created with Sketch. 93.39KB
MSB Ceasing to be a substantial holder15/11/17 download Created with Sketch. 2.58MB
MSB Mesoblast Provides Corporate Update and Q1 Financial ResultsPRICE SENSITIVE15/11/17 download Created with Sketch. 201.68KB
MSB First Quarter Results Presentation15/11/17 download Created with Sketch. 3.73MB
MSB First Quarter Results On Form 6KPRICE SENSITIVE15/11/17 download Created with Sketch. 366.77KB
MSB Becoming a substantial holder13/11/17 download Created with Sketch. 6.28MB
MSB RA Phase 2 Trial Results Presented At ACR Annual MeetingPRICE SENSITIVE13/11/17 download Created with Sketch. 127.42KB
MSB Mesoblast Presents At Credit Suisse Healthcare Conference09/11/17 download Created with Sketch. 71.96KB
MSB Appendix 4C - quarterlyPRICE SENSITIVE31/10/17 download Created with Sketch. 113.37KB
MSB Ceasing to be a substantial holder30/10/17 download Created with Sketch. 1.06MB
MSB Ceasing to be a substantial holder27/10/17 download Created with Sketch. 117.71KB
MSB Becoming a substantial holder27/10/17 download Created with Sketch. 3.99MB
MSB Annual Report to shareholders16/10/17 download Created with Sketch. 2.81MB
MSB Notice of Annual General Meeting/Proxy Form16/10/17 download Created with Sketch. 299.88KB
MSB Appendix 4G and Corporate Governance Statement16/10/17 download Created with Sketch. 184.8KB
MSB Appendix 3B06/10/17 download Created with Sketch. 78.38KB
MSB End-Stage Heart Failure Trial Completes EnrollmentPRICE SENSITIVE28/09/17 download Created with Sketch. 116.85KB
MSB Mesoblast Corporate Updates at Healthcare ConferencesPRICE SENSITIVE25/09/17 download Created with Sketch. 90.75KB
MSB Change of Director's Interest Notices25/09/17 download Created with Sketch. 232.91KB
MSB Appendix 3B18/09/17 download Created with Sketch. 137.7KB
MSB Mesoblast Completes A$50.7 Million Raise15/09/17 download Created with Sketch. 86.49KB
MSB Change of Director Interest and Substantial Holding Notices06/09/17 download Created with Sketch. 321.52KB
MSB Change in substantial holding06/09/17 download Created with Sketch. 80.17KB
MSB Retail Entitlement OfferPRICE SENSITIVE01/09/17 download Created with Sketch. 682.6KB
MSB Mesoblast Reports on Annual and Fourth Quarter ResultsPRICE SENSITIVE30/08/17 download Created with Sketch. 262.07KB
MSB Annual Financial Results Presentation30/08/17 download Created with Sketch. 3.27MB
MSB Preliminary Final Report including Appendix 4EPRICE SENSITIVE30/08/17 download Created with Sketch. 1.33MB
MSB Underwritten A$50.7M Raise Closes Institutional AllocationPRICE SENSITIVE29/08/17 download Created with Sketch. 89.69KB
MSB Cleansing notice25/08/17 download Created with Sketch. 142.32KB
MSB Appendix 3B25/08/17 download Created with Sketch. 138.37KB
MSB Fully Underwritten Entitlement Offer Presentation25/08/17 download Created with Sketch. 3.69MB
MSB Fully Underwritten A$50.7 Million Entitlement OfferPRICE SENSITIVE25/08/17 download Created with Sketch. 171.9KB
MSB Trading HaltPRICE SENSITIVE25/08/17 download Created with Sketch. 333.06KB
MSB Potential For Accelerated Market Entry In Advanced CHFPRICE SENSITIVE23/08/17 download Created with Sketch. 92.24KB
MSB Positive Results of MSB Therapy in Osteoarthritis PublishedPRICE SENSITIVE16/08/17 download Created with Sketch. 111.07KB
MSB Release of shares from voluntary escrow08/08/17 download Created with Sketch. 83.69KB
MSB Appendix 4C - quarterlyPRICE SENSITIVE31/07/17 download Created with Sketch. 96.32KB
MSB Change in substantial holding13/07/17 download Created with Sketch. 278.85KB
MSB Cleansing notice and Appendix 3B10/07/17 download Created with Sketch. 233.9KB
MSB Mesoblast RA Results Presented At EULAR CongressPRICE SENSITIVE22/06/17 download Created with Sketch. 73.88KB
MSB MSB Provides Q3 Operational Highlights and Financial ResultsPRICE SENSITIVE25/05/17 download Created with Sketch. 240.41KB
MSB Third Quarter Results Presentation25/05/17 download Created with Sketch. 2.93MB
MSB Third Quarter Financial Results On Form 6-KPRICE SENSITIVE25/05/17 download Created with Sketch. 3.9MB
MSB Change of Director's Interest Notice02/05/17 download Created with Sketch. 90.45KB
MSB Appendix 4C - quarterlyPRICE SENSITIVE28/04/17 download Created with Sketch. 97.45KB
MSB Change in substantial holding24/04/17 download Created with Sketch. 394.72KB
MSB Successful Interim Analysis in Phase 3 Heart Failure TrialPRICE SENSITIVE10/04/17 download Created with Sketch. 369.91KB
MSB Mesoblast Receives A$3.7m From Aus Govt For R&DPRICE SENSITIVE06/04/17 download Created with Sketch. 65.87KB
MSB FDA Clears Heart Disease Trial At Boston Childrens HospitalPRICE SENSITIVE04/04/17 download Created with Sketch. 93.12KB
MSB Change in substantial holding03/04/17 download Created with Sketch. 317.03KB
MSB Becoming a substantial holder from TEK31/03/17 download Created with Sketch. 110.17KB
MSB Cleansing notice and Appendix 3B31/03/17 download Created with Sketch. 234.09KB
MSB Process Initiated For CHF P3 Interim AnalysisPRICE SENSITIVE31/03/17 download Created with Sketch. 92.03KB
MSB Mesoblast Raises US$40 MillionPRICE SENSITIVE27/03/17 download Created with Sketch. 90.92KB
MSB Durable Three Year Outcomes in Disc DiseasePRICE SENSITIVE15/03/17 download Created with Sketch. 104.05KB
MSB Preliminary Final Report including Appendix 4E
30/08/18PRICE SENSITIVE download Created with Sketch. 1.6MB
MSB UPDATE ON TASLY TRANSACTION
29/08/18PRICE SENSITIVE download Created with Sketch. 89.39KB
MSB Appendix 4C - quarterly
31/07/18PRICE SENSITIVE download Created with Sketch. 117.52KB
MSB Initial Director's Interest Notice
18/07/18 download Created with Sketch. 62.49KB
MSB MSB Enters Into Cardiovascular Alliance For China With Tasly
17/07/18PRICE SENSITIVE download Created with Sketch. 80.49KB
MSB Director Appointment/Resignation
11/07/18 download Created with Sketch. 89.85KB
MSB Appendix 3B
10/07/18 download Created with Sketch. 184.33KB
MSB MSB Enters Into US$50M Financing With NovaQuest Capital
02/07/18PRICE SENSITIVE download Created with Sketch. 80.37KB
MSB Initial and Final Directors' Interest Notices
25/06/18 download Created with Sketch. 140.45KB
MSB ISSCR Presentation on P3 GVHD Trial Survival Benefits
22/06/18 download Created with Sketch. 1.77MB
MSB Key Day 100 Survival Results In P3 GvHD Trial
21/06/18PRICE SENSITIVE download Created with Sketch. 76.22KB
MSB Director Appointment/Resignation
19/06/18 download Created with Sketch. 74.62KB
MSB MSB Provides Q3 Financial Results and Operational Highlights
31/05/18 download Created with Sketch. 212.11KB
MSB Mesoblast Appoints New Chief Financial Officer
31/05/18 download Created with Sketch. 74.97KB
MSB Third Quarter Results Presentation
31/05/18 download Created with Sketch. 965.73KB
MSB Third Quarter Financial Results on Form 6-K
31/05/18PRICE SENSITIVE download Created with Sketch. 515.82KB
MSB Partnership For Allogeneic Cell-based Cancer Immunotherapies
29/05/18PRICE SENSITIVE download Created with Sketch. 77.36KB
MSB Cleansing notice and Appendix 3B
15/05/18 download Created with Sketch. 233.86KB
MSB MSB P3 Results For GVHD Presented At ISCT Meeting
08/05/18 download Created with Sketch. 95.17KB
MSB MSB Cell Therapies Featured At Vatican Healthcare Conference
01/05/18 download Created with Sketch. 73KB
MSB Appendix 4C - quarterly
30/04/18PRICE SENSITIVE download Created with Sketch. 114.44KB
MSB MSB Clinical Program Update For MPC-150-IM In Heart Failure
18/04/18 download Created with Sketch. 106.86KB
MSB Mesoblast Phase 3 CLBP Trial Completes Enrollment
29/03/18 download Created with Sketch. 99.5KB
MSB Change in substantial holding
09/03/18 download Created with Sketch. 187.57KB
MSB MSB Enters Into $75 Million Non-Dilutive Credit Facility
07/03/18PRICE SENSITIVE download Created with Sketch. 91.99KB
MSB Mesoblast Provides Half Year Results and Corporate Update
28/02/18 download Created with Sketch. 237.2KB
MSB Half Year Results Presentation
28/02/18 download Created with Sketch. 3.21MB
MSB Half Year Report and Accounts (including Appendix 4D)
28/02/18PRICE SENSITIVE download Created with Sketch. 558.51KB
MSB GVHD Day 28 Results Presentation
23/02/18PRICE SENSITIVE download Created with Sketch. 1.85MB
MSB Primary Endpoint Successfully Achieved in MSB P3 GVHD Trial
22/02/18PRICE SENSITIVE download Created with Sketch. 103.81KB
MSB Appendix 4C - quarterly
31/01/18PRICE SENSITIVE download Created with Sketch. 96.37KB
MSB Appendix 3B with prospectus
19/01/18PRICE SENSITIVE download Created with Sketch. 481.29KB
MSB Presentation to J.P. Morgan 2018 Healthcare Conference
12/01/18 download Created with Sketch. 3.6MB
MSB Presentation at JP Morgan Healthcare Conference
11/01/18 download Created with Sketch. 69.98KB
MSB Change of Director's Interest Notice
22/12/17 download Created with Sketch. 88.88KB
MSB Mesoblast Receives RMAT For LVAD Heart Failure Patients
21/12/17PRICE SENSITIVE download Created with Sketch. 86.83KB
MSB Release of shares from voluntary escrow
20/12/17 download Created with Sketch. 83.61KB
MSB Mesoblast's P3 GVHD Trial Completes Enrollment
20/12/17PRICE SENSITIVE download Created with Sketch. 93.71KB
MSB Mesoblast Grants TiGenix License For Treatment of Fistulae
15/12/17PRICE SENSITIVE download Created with Sketch. 73.63KB
MSB MSB Named Global Technology Leader In Cell Therapy Industry
08/12/17PRICE SENSITIVE download Created with Sketch. 90.71KB
MSB Change in substantial holding
07/12/17 download Created with Sketch. 280.18KB
MSB Change in substantial holding
05/12/17 download Created with Sketch. 291.65KB
MSB Response to ASX Aware Letter Query
17/11/17PRICE SENSITIVE download Created with Sketch. 508.34KB
MSB Results of Meeting
16/11/17 download Created with Sketch. 172.37KB
MSB CEO Presentation to 2017 Annual General Meeting
16/11/17 download Created with Sketch. 3.72MB
MSB Chairman's Address to Shareholders
16/11/17 download Created with Sketch. 93.39KB
MSB Ceasing to be a substantial holder
15/11/17 download Created with Sketch. 2.58MB
MSB Mesoblast Provides Corporate Update and Q1 Financial Results
15/11/17PRICE SENSITIVE download Created with Sketch. 201.68KB
MSB First Quarter Results Presentation
15/11/17 download Created with Sketch. 3.73MB
MSB First Quarter Results On Form 6K
15/11/17PRICE SENSITIVE download Created with Sketch. 366.77KB
MSB Becoming a substantial holder
13/11/17 download Created with Sketch. 6.28MB
MSB RA Phase 2 Trial Results Presented At ACR Annual Meeting
13/11/17PRICE SENSITIVE download Created with Sketch. 127.42KB
MSB Mesoblast Presents At Credit Suisse Healthcare Conference
09/11/17 download Created with Sketch. 71.96KB
MSB Appendix 4C - quarterly
31/10/17PRICE SENSITIVE download Created with Sketch. 113.37KB
MSB Ceasing to be a substantial holder
30/10/17 download Created with Sketch. 1.06MB
MSB Ceasing to be a substantial holder
27/10/17 download Created with Sketch. 117.71KB
MSB Becoming a substantial holder
27/10/17 download Created with Sketch. 3.99MB
MSB Annual Report to shareholders
16/10/17 download Created with Sketch. 2.81MB
MSB Notice of Annual General Meeting/Proxy Form
16/10/17 download Created with Sketch. 299.88KB
MSB Appendix 4G and Corporate Governance Statement
16/10/17 download Created with Sketch. 184.8KB
MSB Appendix 3B
06/10/17 download Created with Sketch. 78.38KB
MSB End-Stage Heart Failure Trial Completes Enrollment
28/09/17PRICE SENSITIVE download Created with Sketch. 116.85KB
MSB Mesoblast Corporate Updates at Healthcare Conferences
25/09/17PRICE SENSITIVE download Created with Sketch. 90.75KB
MSB Change of Director's Interest Notices
25/09/17 download Created with Sketch. 232.91KB
MSB Appendix 3B
18/09/17 download Created with Sketch. 137.7KB
MSB Mesoblast Completes A$50.7 Million Raise
15/09/17 download Created with Sketch. 86.49KB
MSB Change of Director Interest and Substantial Holding Notices
06/09/17 download Created with Sketch. 321.52KB
MSB Change in substantial holding
06/09/17 download Created with Sketch. 80.17KB
MSB Retail Entitlement Offer
01/09/17PRICE SENSITIVE download Created with Sketch. 682.6KB
MSB Mesoblast Reports on Annual and Fourth Quarter Results
30/08/17PRICE SENSITIVE download Created with Sketch. 262.07KB
MSB Annual Financial Results Presentation
30/08/17 download Created with Sketch. 3.27MB
MSB Preliminary Final Report including Appendix 4E
30/08/17PRICE SENSITIVE download Created with Sketch. 1.33MB
MSB Underwritten A$50.7M Raise Closes Institutional Allocation
29/08/17PRICE SENSITIVE download Created with Sketch. 89.69KB
MSB Cleansing notice
25/08/17 download Created with Sketch. 142.32KB
MSB Appendix 3B
25/08/17 download Created with Sketch. 138.37KB
MSB Fully Underwritten Entitlement Offer Presentation
25/08/17 download Created with Sketch. 3.69MB
MSB Fully Underwritten A$50.7 Million Entitlement Offer
25/08/17PRICE SENSITIVE download Created with Sketch. 171.9KB
MSB Trading Halt
25/08/17PRICE SENSITIVE download Created with Sketch. 333.06KB
MSB Potential For Accelerated Market Entry In Advanced CHF
23/08/17PRICE SENSITIVE download Created with Sketch. 92.24KB
MSB Positive Results of MSB Therapy in Osteoarthritis Published
16/08/17PRICE SENSITIVE download Created with Sketch. 111.07KB
MSB Release of shares from voluntary escrow
08/08/17 download Created with Sketch. 83.69KB
MSB Appendix 4C - quarterly
31/07/17PRICE SENSITIVE download Created with Sketch. 96.32KB
MSB Change in substantial holding
13/07/17 download Created with Sketch. 278.85KB
MSB Cleansing notice and Appendix 3B
10/07/17 download Created with Sketch. 233.9KB
MSB Mesoblast RA Results Presented At EULAR Congress
22/06/17PRICE SENSITIVE download Created with Sketch. 73.88KB
MSB MSB Provides Q3 Operational Highlights and Financial Results
25/05/17PRICE SENSITIVE download Created with Sketch. 240.41KB
MSB Third Quarter Results Presentation
25/05/17 download Created with Sketch. 2.93MB
MSB Third Quarter Financial Results On Form 6-K
25/05/17PRICE SENSITIVE download Created with Sketch. 3.9MB
MSB Change of Director's Interest Notice
02/05/17 download Created with Sketch. 90.45KB
MSB Appendix 4C - quarterly
28/04/17PRICE SENSITIVE download Created with Sketch. 97.45KB
MSB Change in substantial holding
24/04/17 download Created with Sketch. 394.72KB
MSB Successful Interim Analysis in Phase 3 Heart Failure Trial
10/04/17PRICE SENSITIVE download Created with Sketch. 369.91KB
MSB Mesoblast Receives A$3.7m From Aus Govt For R&D
06/04/17PRICE SENSITIVE download Created with Sketch. 65.87KB
MSB FDA Clears Heart Disease Trial At Boston Childrens Hospital
04/04/17PRICE SENSITIVE download Created with Sketch. 93.12KB
MSB Change in substantial holding
03/04/17 download Created with Sketch. 317.03KB
MSB Becoming a substantial holder from TEK
31/03/17 download Created with Sketch. 110.17KB
MSB Cleansing notice and Appendix 3B
31/03/17 download Created with Sketch. 234.09KB
MSB Process Initiated For CHF P3 Interim Analysis
31/03/17PRICE SENSITIVE download Created with Sketch. 92.03KB
MSB Mesoblast Raises US$40 Million
27/03/17PRICE SENSITIVE download Created with Sketch. 90.92KB
MSB Durable Three Year Outcomes in Disc Disease
15/03/17PRICE SENSITIVE download Created with Sketch. 104.05KB
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
Add to My Watchlist
(20min delay)
Last
$2.28
Change
-0.010(0.44%)
Mkt cap ! $2.918B
Open High Low Value Volume
$2.26 $2.31 $2.25 $3.303M 1.445M

Buyers (Bids)

No. Vol. Price($)
41 58333 $2.27
 

Sellers (Offers)

Price($) Vol. No.
$2.28 60681 23
View Market Depth
Last trade - 15.17pm 12/08/2025 (20 minute delay) ?
Last
$2.29
  Change
-0.010 ( 0.55 %)
Open High Low Volume
$2.27 $2.31 $2.26 505250
Last updated 15.36pm 12/08/2025 ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.